Business
Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update
Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 an...
About this update from Devonian Health Group, Inc.
[{"type":"text","content":"\n\n\nDevonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nCompany continues preclinical studies for Thykamine™ in MASH and Fibrosis, furthering the understanding of Thykamine™'s mechanism of action.Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs published in the peer reviewed journal, Biomedicines.Design for Thykamine™ Phase 2/3 clinical study in pediatric Atopic Dermatitis is complete based on the positive results of the phase 2 in an adult population.Thykamine™ radiodermatitis pivotal clinical study in the process of being initiated.First quarter gross margin on distribution revenues of $0.5 millionFirst quarter net loss of $1.6 million dollars, ($0.01) per sharePrivate placements completed with gross proceeds of $2.7 millionCash as of October 31, 2025 of $6.6 million; Company remains debt freeQUÉBEC, Dec. 12, 2025 /CNW/ - Devonian Health Group Inc. (\"Devonian\" or the \"Company\") (TSXV: GSD) (OTCQB: DVHGF), today announced operating and financial results for its first quarter ended on October 31, 2025.\n\n\n\n\n\n\n\nManagement Comments\n''We are very pleased with the continued momentum across both our therapeutic and commercial activities this quarter. Thykamine™'s progress in preclinical MASH and fibrosis strengthens its profile as a promising first-in-class anti-inflammatory candidate, while the readiness of our Phase 2/3 pediatric atopic dermatitis study marks an important milestone toward addressing a significant unmet medical need. Our gross margin performance, combined with the successful completion of $2.7 million in private placements, reflects growing confidence in our strategy and in the long-term value of our pipeline'' said Dr Andre Boulet, PhD, Chief Executive Officer of Devonian.\nBusiness Highlights\nThe Company finalized the protocol for a 12-week, multicenter, randomized, double-blind, vehicle-controlled, Phase 2/3 clinical study investigating...